{"altmetric_id":8072014,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":2},"twitter":{"unique_users_count":2,"unique_users":["I2BHouston","METUPorg"],"posts_count":2}},"citation":{"altmetric_jid":"4f6fa62b3cf058f610007f12","authors":["Lord R","Nair S","Schache A","Spicer J","Somaihah N","Khoo V","Pandha H","R. Lord","S. Nair","A. Schache","J. Spicer","Navita Somaihah","V. Khoo","H. Pandha"],"doi":"10.1016\/j.juro.2007.01.143","endpage":"2140","first_seen_on":"2016-05-21T05:47:54+00:00","issns":["0022-5347","00225347"],"issue":"6","journal":"The Journal of Urology","last_mentioned_on":1504041788,"links":["https:\/\/www.ncbi.nlm.nih.gov\/m\/pubmed\/17509300\/"],"pmid":"17509300","pubdate":"2007-06-14T23:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"2136","title":"Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022534707002819","volume":"177","mendeley_url":"http:\/\/www.mendeley.com\/research\/low-dose-metronomic-oral-cyclophosphamide-hormone-resistant-prostate-cancer-phase-ii-study-3"},"altmetric_score":{"score":1.35,"score_history":{"1y":1.35,"6m":1.35,"3m":1.35,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1.35},"context_for_score":{"all":{"total_number_of_other_articles":8446126,"mean":7.1012113779909,"rank":4201364,"this_scored_higher_than_pct":49,"this_scored_higher_than":4180355,"rank_type":"exact","sample_size":8446126,"percentile":49},"similar_age_3m":{"total_number_of_other_articles":274070,"mean":11.689859298205,"rank":133553,"this_scored_higher_than_pct":50,"this_scored_higher_than":137876,"rank_type":"exact","sample_size":274070,"percentile":50},"this_journal":{"total_number_of_other_articles":8452,"mean":4.9014123772335,"rank":4888,"this_scored_higher_than_pct":41,"this_scored_higher_than":3519,"rank_type":"exact","sample_size":8452,"percentile":41},"similar_age_this_journal_3m":{"total_number_of_other_articles":380,"mean":9.9215039577836,"rank":303,"this_scored_higher_than_pct":20,"this_scored_higher_than":77,"rank_type":"exact","sample_size":380,"percentile":20}}},"demographics":{"poster_types":{"member_of_the_public":2},"users":{"twitter":{"cohorts":{"Members of the public":2}},"mendeley":{"by_status":{"Researcher":1,"Student  > Ph. D. Student":1,"Student  > Master":1},"by_discipline":{"Medicine and Dentistry":1,"Agricultural and Biological Sciences":2}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/I2BHouston\/statuses\/902387152427864064","license":"gnip","citation_ids":[8072014],"posted_on":"2017-08-29T04:27:17+00:00","author":{"name":"P Zhang MD PhD ABIHM","url":"http:\/\/www.I2B.us","image":"https:\/\/pbs.twimg.com\/profile_images\/901220158752018432\/Zm72fQZy_normal.jpg","description":"\ud83e\udd1dInstitute of Integrative BioOncology(I2B) offers biology-informed precision total therapy for  metastatic cancers. Expand your options \u260e\ufe0f7137971900","id_on_source":"I2BHouston","tweeter_id":"901216620214984706","geo":{"lt":null,"ln":null},"followers":182},"tweet_id":"902387152427864064"},{"url":"http:\/\/twitter.com\/METUPorg\/statuses\/902642802093309952","license":"gnip","rt":["I2BHouston"],"citation_ids":[8072014],"posted_on":"2017-08-29T21:23:08+00:00","author":{"name":"METUP","url":"http:\/\/metup.org","image":"https:\/\/pbs.twimg.com\/profile_images\/618450956414382080\/a0sDiQ4Q_normal.png","description":"METUP is committed to changing the landscape of metastatic cancer through direct action.","id_on_source":"METUPorg","tweeter_id":"3236457505","geo":{"lt":null,"ln":null},"followers":3453},"tweet_id":"902642802093309952"}]}}